| 产品详情 |
| Edit |   |
|---|
| Product Name | Ponatinib |
|---|
| Description | Purity >98%. Ponatinib is an orally available, pan-Bcr-Abl tyrosine kinase inhibitor developed for the treatment of an advanced phase of chronic myeloid leukemia in which mutations of the kinase endow resistance to other Bcr-Abl inhibitors. Ponatinib potently inhibits native Bcr-Abl (IC50 = 0.37 nM) as well as various clinically important mutant forms including Bcr-AblT315I (IC50 = 2 nM). It can also inhibit c-Src (IC50 = 5.4 nM) and VEGFR, FGFR, and PDGFR receptor tyrosine kinases (IC50 s = 1-2 nM), yet is >1,000-fold selective against family members of Aurora kinase, insulin receptor kinase, or cyclin-dependent kinase. Ponatinib has been shown to inhibit proliferation of Ba/F3 cells expressing native (IC50 = 0.5 nM) or mutant (IC50 s = 0.5-36 nM) Bcr-Abl by inducing apoptosis. In a Ba/F3 Bcr- AblT315I xenograft model, tumor growth was inhibited in mice upon oral dosing at 10-30 mg/kg. |
|---|
| Size | n/a |
|---|
| Concentration | n/a |
|---|
| Applications | n/a |
|---|
| Other Names | 3-(2-imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-[4-[(4-methyl-1-piperazinyl)methyl]-3-(trifluoromethyl)phenyl]-benzamide, AP 24534, Iclusig |
|---|
| Gene, Accession, CAS # | CAS: 943319-70-8 |
|---|
| Catalog # | LS-H9476 |
|---|
| Price | |
|---|
| Order / More Info | Ponatinib from LIFESPAN BIOSCIENCES INC. |
|---|
| Product Specific References | n/a |
|---|
| 产品资料 |
|
|